This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Acute myeloid leukaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder characterised by the arrest of differentiation of the progenitor cells (“blasts”) coupled with an accumulation of immature progenitors in the bone marrow, resulting in hematopoietic failure (1).

  • AML is generally a disease of older adults - median age at diagnosis between 65 and 70 year of age
  • after age 5-10, every year of age worsens the prognosis for patients with AML
  • AML in older individuals is a more recalcitrant disease
    • the disease tends to be less proliferative with average bone marrow blast counts of 20% in those older than 60 and 40% in those younger than 60. When compared with those younger than 56, those older than 56 are less likely to have favorable cytogenetics (16% vs. 5%) and more likely to have unfavorable cytogenetics (33% vs. 50%)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.